HilleVax, Inc. Balance Sheet | Understand Stock

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022
Assets
Current assets:
Cash and cash equivalents
Marketable securities
Prepaid expenses and other current assets
Assets held for sale, net
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Restricted cash
Other assets
Total assets
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued expenses
Accrued interest
Convertible promissory notes payable at fair value (includes related party amounts of $0 and $40,580, respectively)
Current portion of long-term debt, net of debt discount
Current portion of operating lease liability
Warrant liabilities - related party
Total current liabilities

Operating lease liability, net of current portion
Long-term debt, net of debt discount
Other long-term liabilities
Total liabilities
Stockholders' equity:
Common stock, $0.0001 par value; authorized shares- 500,000,000 at June 30, 2025 and December 31, 2024; issued shares-50,141,064 and 49,852,391 at June 30, 2025 and December 31, 2024, respectively; outstanding shares-50,125,541 and 49,719,448 at June 30, 2025 and December 31, 2024, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments